

Ref: ASCL/SEC/2023-24/61

March 27, 2024

1. To. The General Manager Department of Corporate Services **BSE Limited** 1st Floor, New Trading Ring Rotunda Building, P. J. Tower

Dalal Street, Fort

Mumbai - 400 001 BSE Scrip Code: 532853 2. To, The General Manager (Listing) National Stock Exchange of India Ltd 5th Floor, Exchange Plaza Plot No. C/1, G Block Bandra - Kurla Complex Bandra (East)

Mumbai - 400 051

**NSE Trading Symbol: ASAHISONG** 

SUB: DISCLOSURE / INTIMATION OF ACQUISITION OF STAKE

REF: REGULATION 30 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ("SEBI LISTING REGUALTIONS")

Dear Sirs,

We wish to inform you that Asahi Songwon Colors Limited ("the Company") has acquired remaining 6,60,000 shares i.e. 22% stake in Atlas Life Sciences Private Limited ("ALSPL") on March 26, 2024.

Pursuant to said acquisition of remaining 22% stake in ALSPL, the Company's shareholding in ALSPL has increased from 78% (pre-acquisition) to 100% (post acquisition) and ALSPL became Wholly Owned Subsidiary (WOS) of the Company.

ALSPL is one of the leading manufacturers of Active Pharmaceutical Ingredients (API) and Bulk Drugs, with dominant position in Pregabalin (PG) and 4 other API's and one intermediate (R-CMH for PG).







The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 is attached as per "Annexure - A".

Kindly take the above information on your records.

Thanking you,

Yours faithfully, For, ASAHI SONGWON COLORS LIMITED

JOSEPH SAJI VARGHESE

Digitally signed by JOSEPH SAJI VARGHESE Date: 2024.03.27 13:22:24 +05'30'

SAJI JOSEPH Company Secretary and Compliance Officer

Encl: As above







## Annexure - A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023.

- a) Name of the target entity, i)
  details in brief such as Pr
  size, turnover etc
- i) Name of the Target: Atlas Life Sciences Private Limited ("ALSPL")
  - ii) Business of the Target: ALSPL is one of the leading manufacturers of Active Pharmaceutical Ingredients (API) and Bulk Drugs. ALSPL product portfolio includes Pregabalin, R-Compund, Phenylephrine HCL, Gliclazide, Amisulpride and Levosulpiride.
  - iii) Financial details as per the audited financial statements for the Financial Year 2022-2023:

Turnover: Rs. 51,041.07 Lakhs

Earning before interest, taxes, depreciation and amortization (EBITDA): Rs. (1,774.17) lakhs.

b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? if yes, nature of interest and details thereof and whether the same is done at "arms-length";

The acquisition falls within related party transaction in term of regulation 2(zc) of the SEBI Listing Regulations.

The promoter/promoter group companies of the Company do not have any interest in the entity being acquired.

## Asahi Songwon Colors Ltd.

CIN: L24222GJ1990PLC014789

Regd. Office: "Asahi House", 20, Times Corporate Park, Thaltej – Shilaj Road, Thaltej, Ahmedabad – 380 059, Gujarat, India.

Tele: 91-79 6832 5000 • Fax: 91-79 6832 5099 • Web Site: www.asahisongwon.com







| c) | Industry to which the entity                         | Manufacturing of Active Pharmaceutical   |
|----|--|--|
|    | being acquired belongs;                              | Ingredient (API) and Bulk Drugs.   |
|    |  |  |
| d) | Objects and effects of                               | Asahi Songwon Colors Limited ("Company")   |
|    | acquisition (including but                           | in order to add a new growth lever and to  |
|    | not limited to, disclosure of                        | create significant value by leveraging   |
|    | reasons for acquisition of                           | combined capabilities and unlock synergies   |
|    | target entity, if its business                       | entered into API and Bulk Drug business.   |
|    | is outside the main line of                          | The API business of ALSPL has diversified  |
|    | business of the listed                               | portfolio of 6+ products with several of them  |
|    | entity);   | in R&D product pipeline.   |
|    |  |  |
| e) | Brief details of any                                 | Not applicable   |
|    | government or regulatory                             |  |
|    | approvals required for the                           |  |
|    | acquisition;   | · ·  |
| ŋ  | Indicative time of                                   | The acquisition of shares under first tranche  |
|    | completion of the                                    | i.e. 78% stake in ALSPL was completed on   |
|    | acquisition;   | April 18, 2022 in terms of Share Purchase  |
|    |  | Agreement dated April 18, 2022 and the   |
|    |  | Balance 22% stake in ALSPL is Acquired on  |
|    |  | March 26, 2024.  |
|    |  | D  |
|    |  | Pursuant to said acquisition of remaining  |
|    | a a  | 22% stake in ALSPL, 100% acquisition has   |
| L. |  | been completed.  |
| g) | Nature of consideration -                            | Cash Consideration. The acquisition of   |
|    | whether cash consideration                           | Commence of the commence of th |
|    | or share swap and details                            | shares of ALSPL representing 78% stake in ALSPL was completed on April 18, 2022 for  |
| L  | of the same;   | a consideration of INR 4800 Lakhs.   |
| h) | Cost of acquisition or the price at which the shares | a consideration of hir tood Danies.  |
|    | are acquired;  | Balance 6,60,000 shares representing 22%   |
| 3) | Percentage of shareholding/                          | stake in ALSPL is acquired in single tranche   |
| 1, | control acquired and / or                            | on March 26, 2024 for a consideration of Rs.   |
|    | number of shares acquired                            | INR 965 Lakhs.   |
|    | number of shares acquired                            | The your Burnio.   |
| j) | Brief background about the                           | i) Line of business:   |
| 3, | entity acquired in terms of                          | ALSPL is one of the leading manufacturers of   |
|    | products/line of business                            | Active Pharmaceutical Ingredients (API) and  |
|    | acquired, date of                                    | Bulk Drugs. The Companies product portfolio  |
|    | incorporation, history of                            |  |
|    |  |  |

## Asahi Songwon Colors Ltd.

CIN: L24222GJ1990PLC014789

ISO14001:2015 Registered IMS-QE/JAS-C0061/0403





last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) Phenylephrine HCL, Gliclazide, Amisulpride and Levosulpiride.

ii) Date of Incorporation: ALSPL is incorporated on April 22, 2004 in India.

iii) Turnover of last three financial years

| Financial Year | Turnover (Amount in Lakhs) |
|----------------|----------------------------|
| FY 2022-23     | 13,589.49                  |
| FY 2021-22     | 14,845.52                  |
| FY 2020-21     | 10,929.00                  |

For, ASAHI SONGWON COLORS LIMITED

JOSEPH SAJI

Digitally signed by JOSEPH SAJI VARGHESE

**VARGHESE** 

Date: 2024.03.27 13:23:20 +05'30'

SAJI JOSEPH

Company Secretary and Compliance Officer

CIN: L24222GJ1990PLC014789

Regd. Office: "Asahi House", 20, Times Corporate Park, Thaltej – Shilaj Road, Thaltej, Ahmedabad – 380 059, Gujarat, India.





Thaltej, Ahmedabad – 380 059, Gujarat, India. Tele: 91-79 6832 5000 • Fax: 91-79 6832 5099 • Web Site: www.asahisongwon.com